2007 - Fellow of the American Association for the Advancement of Science (AAAS)
Member of the Association of American Physicians
His primary areas of study are Internal medicine, Interleukin, Immunology, Tumor necrosis factor alpha and Endocrinology. His work carried out in the field of Internal medicine brings together such families of science as Gastroenterology and Hereditary angioedema. Jeffrey A. Gelfand has included themes like Platelet, In vitro and Septic shock in his Interleukin study.
The study incorporates disciplines such as Necrosis, Shock and Microbiology in addition to Septic shock. His Immunology study incorporates themes from Clindamycin, Regimen, Radioimmunoassay and Babesia. He works mostly in the field of Tumor necrosis factor alpha, limiting it down to topics relating to Peripheral blood mononuclear cell and, in certain cases, Gene expression, Complement system and Lipopolysaccharide.
Jeffrey A. Gelfand focuses on Immunology, Internal medicine, Endocrinology, Interleukin and Immune system. Immunology connects with themes related to Molecular biology in his study. His research integrates issues of Gastroenterology and Hereditary angioedema in his study of Internal medicine.
In his works, he performs multidisciplinary study on Endocrinology and Danazol. His Interleukin research is multidisciplinary, relying on both Tumor necrosis factor alpha, In vitro, Lipopolysaccharide, Receptor and Radioimmunoassay. His Tumor necrosis factor alpha research is multidisciplinary, incorporating perspectives in Peripheral blood mononuclear cell and Shock.
Jeffrey A. Gelfand mainly investigates Immune system, Antibody, Cancer research, Antimicrobial and Microbiology. His Immune system study necessitates a more in-depth grasp of Immunology. His Antibody study combines topics from a wide range of disciplines, such as Protein domain, Internal medicine, Fusion protein and Severe acute respiratory syndrome coronavirus 2.
Jeffrey A. Gelfand combines subjects such as Immunoglobulin M, Immunoassay and Seroprevalence with his study of Internal medicine. His Cancer research research is multidisciplinary, incorporating elements of Tumor microenvironment, Cancer, Immunotherapy and Combination therapy. His work in the fields of Microbiology, such as Antibiotic resistance and Neisseria gonorrhoeae, intersects with other areas such as Genotoxicity, Gonorrhea and ABL.
Jeffrey A. Gelfand mostly deals with Escherichia coli, Antibody, Tumor microenvironment, Cancer research and CXCR4 antagonist. His Escherichia coli research also works with subjects such as
Jeffrey A. Gelfand interconnects Immunoassay and Immunoglobulin G, Immunoglobulin M in the investigation of issues within Internal medicine. His biological study spans a wide range of topics, including CD40, Immunosuppression and CD8, Immune system, Antigen. His Serology study is concerned with the larger field of Immunology.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition.
S Okusawa;J A Gelfand;T Ikejima;R J Connolly.
Journal of Clinical Investigation (1988)
Circulating Interleukin-1 and Tumor Necrosis Factor in Septic Shock and Experimental Endotoxin Fever
J.G. Cannon;R.G. Tompkins;J.A. Gelfand;H.R. Michie.
The Journal of Infectious Diseases (1990)
Treatment of Hereditary Angioedema with Danazol
Jeffrey A. Gelfand;Richard J. Sherins;David W. Alling;Michael M. Frank.
The New England Journal of Medicine (1976)
Hereditary angioedema: the clinical syndrome and its management.
Michael M. Frank;Jeffrey A. Gelfand;John P. Atkinson.
Annals of Internal Medicine (1976)
Anticytokine Strategies in the Treatment of the Systemic Inflammatory Response Syndrome
Charles A. Dinarello;Jeffrey A. Gelfand;Sheldon M. Wolff.
A specific receptor antagonist for interleukin 1 prevents Escherichia coli-induced shock in rabbits.
Go Wakabayashi;Jeffrey A. Gelfand;John F. Burke;Robert C. Thompson.
The FASEB Journal (1991)
Staphylococcus epidermidis induces complement activation, tumor necrosis factor and interleukin-1, a shock-like state and tissue injury in rabbits without endotoxemia. Comparison to Escherichia coli.
G Wakabayashi;J A Gelfand;W K Jung;R J Connolly.
Journal of Clinical Investigation (1991)
Recombinant C5a stimulates transcription rather than translation of interleukin-1 (IL-1) and tumor necrosis factor: translational signal provided by lipopolysaccharide or IL-1 itself
Ralf Schindler;Jeffrey A. Gelfand;Charles A. Dinarello..
Persistent and relapsing babesiosis in immunocompromised patients.
Peter J. Krause;Benjamin E. Gewurz;Benjamin E. Gewurz;David Hill;Francisco M. Marty.
Clinical Infectious Diseases (2008)
Replacement therapy in hereditary angioedema: successful treatment of acute episodes of angioedema with partly purified C1 inhibitor.
James E. Gadek;Stephen W. Hosea;Jeffrey A. Gelfand;Maria Santaella.
The New England Journal of Medicine (1980)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: